Nightfood Holdings Inc. (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC), marked by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. This deployment extends the initiative beyond Phase 1 materials logistics operations into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility, where the systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology and life sciences environments, with PUR-E operating as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform.
The importance of this announcement lies in its potential to transform pharmaceutical manufacturing by integrating autonomous systems into sterile environments, which are critical for producing injectable drugs. By deploying robots like PUR-E, the industry can enhance operational efficiency, reduce human error, and ensure compliance with stringent cGMP standards. This could lead to faster production cycles, lower costs, and improved safety for both workers and patients. For the broader industry, it signals a shift toward increased automation in regulated settings, addressing labor shortages and productivity demands.
Nightfood Holdings, doing business as TechForce Robotics, focuses on AI-enhanced robotics and automation across multiple industries. Through its vertically integrated business model, the company combines proprietary robotics technology, AI-enhanced software, and strategic manufacturing partnerships. Its Robotics-as-a-Service (RaaS) model provides flexible, scalable automation solutions while generating recurring revenue. As the company expands into pharmaceutical automation, it leverages partnerships like the one with Oncotelic to accelerate innovation.
For more details, the full press release is available at https://ibn.fm/mXU1p. Additional updates on NGTF can be found in the company’s newsroom at http://ibn.fm/NGTF.
This development underscores the growing role of robotics in life sciences, with potential impacts on manufacturing efficiency and drug availability. The successful integration of autonomous systems in sterile environments could set a precedent for wider adoption across the pharmaceutical industry, ultimately benefiting patients through more reliable and cost-effective drug production.
